<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Rippa A</submitter><funding>NIDDK NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>Foundation for the National Institutes of Health</funding><funding>Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)</funding><pagination>11379</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12727770</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>A high-definition description of pancreatic islets would prove beneficial for understanding the pathophysiology of type 1 diabetes (T1D), yet significant knowledge gaps exist in terms of their size, endocrine cell composition, and number in both health and disease. Here, 3-dimensional (3D) analyses of pancreata from control persons without diabetes (ND) demonstrate approximately 50% of islets are insulin-positive (INS + ) glucagon-negative (GCG-). Non-diabetic individuals positive for a single Glutamic acid decarboxylase autoantibody (GADA + ) yet at increased risk for disease consistently demonstrate endocrine features, including islet volume and cell composition, closely resembling the age-matched ND controls. In contrast, pancreata from individuals with short-duration T1D demonstrate significantly reduced islet density and a dramatic loss of INS + GCG- islets with preservation of large INS + GCG+ islets. The size and cellular composition of pancreatic islets may, therefore, represent influential factors that impact β-cell loss during T1D disease progression.</pubmed_abstract><journal>Nature communications</journal><pubmed_title>3D imaging of human pancreas suggests islet size and endocrine composition influence their loss in type 1 diabetes.</pubmed_title><pmcid>PMC12727770</pmcid><funding_grant_id>R01 DK131059</funding_grant_id><funding_grant_id>R01 DK123292</funding_grant_id><funding_grant_id>U24 DK104162</funding_grant_id><funding_grant_id>R01DK131059</funding_grant_id><funding_grant_id>P01 AI042288</funding_grant_id><funding_grant_id>P01AI042288</funding_grant_id><funding_grant_id>R01DK123292</funding_grant_id><funding_grant_id>U01 DK135001</funding_grant_id><pubmed_authors>Rippa A</pubmed_authors><pubmed_authors>Currlin S</pubmed_authors><pubmed_authors>Kaddis JS</pubmed_authors><pubmed_authors>Williams MD</pubmed_authors><pubmed_authors>Wasserfall CH</pubmed_authors><pubmed_authors>Atkinson MA</pubmed_authors><pubmed_authors>Kusmartseva I</pubmed_authors><pubmed_authors>Posgai AL</pubmed_authors><pubmed_authors>Brusko M</pubmed_authors><pubmed_authors>Campbell-Thompson M</pubmed_authors></additional><is_claimable>false</is_claimable><name>3D imaging of human pancreas suggests islet size and endocrine composition influence their loss in type 1 diabetes.</name><description>A high-definition description of pancreatic islets would prove beneficial for understanding the pathophysiology of type 1 diabetes (T1D), yet significant knowledge gaps exist in terms of their size, endocrine cell composition, and number in both health and disease. Here, 3-dimensional (3D) analyses of pancreata from control persons without diabetes (ND) demonstrate approximately 50% of islets are insulin-positive (INS + ) glucagon-negative (GCG-). Non-diabetic individuals positive for a single Glutamic acid decarboxylase autoantibody (GADA + ) yet at increased risk for disease consistently demonstrate endocrine features, including islet volume and cell composition, closely resembling the age-matched ND controls. In contrast, pancreata from individuals with short-duration T1D demonstrate significantly reduced islet density and a dramatic loss of INS + GCG- islets with preservation of large INS + GCG+ islets. The size and cellular composition of pancreatic islets may, therefore, represent influential factors that impact β-cell loss during T1D disease progression.</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Dec</publication><modification>2026-06-06T05:15:59.129Z</modification><creation>2026-05-26T03:12:07.956Z</creation></dates><accession>S-EPMC12727770</accession><cross_references><pubmed>41381473</pubmed><doi>10.1038/s41467-025-66198-6</doi></cross_references></HashMap>